Tacalcitol monohydrate
(Synonyms: 他骨化醇一水物,1,24(R)-Dihydroxyvitamin D3 monohydrate) 目录号 : GC37714Analog of 1,25-
Cas No.:93129-94-3
Sample solution is provided at 25 µL, 10mM.
Vitamin D aids in the absorption of calcium and has central roles in bone formation and maintenance, hypertension, cancer, and immunity.1,2 In addition, the active form of vitamin D, 1,25-
1.Holick, M.F.Vitamin D deficiencyN. Engl. J. Med.357(3)266-281(2007) 2.Peterlik, M., Boonen, S., Cross, H.S., et al.Vitamin D and calcium insufficiency-related chronic diseases: An emerging world-wide public health problemInt. J. Environ. Res. Public Health6(10)2585-2607(2009) 3.Bikle, D.D.1,25(OH)2D3-regulated human keratinocyte proliferation and differentiation: Basic studies and their clinical applicationJ. Nutr.1251709S-1714S(1995) 4.Leone, G., and Pacifico, A.Profile of clinical efficacy and safety of topical tacalcitolActa Biomed.76(1)13-19(2005) 5.Prignano, F., Buggiani, G., and Lotti, T.Clinical evaluation of topical tacalcitol efficacy in extending the remission period between nb-UVB phototherapy cycles in psoriatic patientsActa Biomed.8051-56(2009) 6.Matsumoto, K., Hashimoto, K., Kiyoki, M., et al.Effect of 1,24R-dihydroxyvitamin D3 on the growth of human keratinocytesJ. Dermatol.17(2)97-103(1990) 7.Fukuoka, M., Ogino, Y., Sato, H., et al.Regulation of RANTES and IL-8 production in normal human dermal fibroblasts by active vitamin D3 (tacalcitol)Br. J. Pharmacol.124(7)1433-1438(1998) 8.Yamanaka, K.I., Kakeda, M., Kitagawa, H., et al.1,24-Dihydroxyvitamin D3 (tacalcitol) prevents skin T-cell infiltrationBr. J. Dermatol.162(6)1206-1215(2010)
Cas No. | 93129-94-3 | SDF | |
别名 | 他骨化醇一水物,1,24(R)-Dihydroxyvitamin D3 monohydrate | ||
Canonical SMILES | CC([C@@H](CC[C@H]([C@@H](CC[C@]1/2[H])[C@@]1(C)CCCC2=C/C=C3C[C@@H](C[C@H](C/3=C)O)O)C)O)C.[H]O[H] | ||
分子式 | C27H46O4 | 分子量 | 434.65 |
溶解度 | DMF: 20 mg/ml,DMSO: 20 mg/ml,Ethanol: 20 mg/ml,Ethanol:PBS (pH 7.2) (1:3): 0.30 mg/ml | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.3007 mL | 11.5035 mL | 23.007 mL |
5 mM | 0.4601 mL | 2.3007 mL | 4.6014 mL |
10 mM | 0.2301 mL | 1.1504 mL | 2.3007 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet